|
|
Article: Targeted Genetics Expands AAV Vector Patent Portfolio.
- Article from:
- PR Newswire
- Article date:
- May 17, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SEATTLE, May 17 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation today announced the issuance of an additional patent related to its adeno-associated virus (AAV) vector technology. U.S. patent #6,893,865, titled "Methods, Compositions and Cells for Encapsidating Recombinant Vectors in AAV Particles," expands Targeted Genetics' AAV vector systems used for gene delivery. Targeted Genetics' leading gene delivery vehicle, AAV, is used to deliver a gene of interest into cells of the patient to impact disease. The Company uses AAV technology for its current development programs targeting AIDS prophylaxis, inflammatory arthritis, hyperlipidemia, congestive heart ...